83-2271-65　［受注停止］KRIBIOLISA Ibrutinib （IMBRUVICA） ELISA 1 x 96 wells　KOD1025

特徴

• Description：Enzyme Immunoassay for the quantitative determination of Ibrutinib
• in serum, plasma and cell culture supernatant
• Ibrutinib （Imbruvica） is a small molecule drug that binds permanently to a protein, Bruton's tyrosine kinase
• （BTK）, and it is important in B cells.
• It is used to treat B cell cancers like mantle cell lymphoma, chronic
• lymphocytic leukemia, and Waldenstrom's macroglobulinemia.
• About the kit：
• - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
• - Recovery rates are between 85 - 115％
• - Ready to use with a standard protocol with break-apart pre-coated wells
• - Validated as per US FDA guidelines for Bioassays
• - Optimized for matrix effects to ensure higher sensitivity.
• - Shelf life： 1 year
• The Ibrutinib ELISA is a competitive immunoassay for the determination of Ibrutinib.
• A constant
• concentration of Tracer; varying concentrations of unlabeled standard and BTK are added in sequence to
• the uncoated microtitre plate wells and incubated.
• After 1st incubation, Anti- BTK Antibody is dispensed to all
• wells of uncoated Microtitre plate containing the reaction mixture and incubated.
• After 2nd incubation, all
• reaction mixtures are transferred to the respective wells of coated microtitre plate and incubated.
• After
• washing, Streptavidin HRP conjugate is added and incubated.
• Captured Tracer is subsequently bound by
• streptavidin HRP which produces a soluble colored product after addition of TMB substrate.
• The enzyme
• reaction is stopped by dispensing of stop solution into the wells.
• The optical density （OD） of the solution at
• 450 nm is inversely proportional to the amount of bound Ibrutinib molecule present in standards or samples.